According to a recent survey from Oracle Health Sciences, 97% of trial professionals say newly adopted approaches will stay in use as we move beyond COVID-19.
Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.
A leader from the language and tech solutions firm explains how multilingual support can improve patient recruitment and other aspects of clinical trials.
The radvocacy group is joining with the Rare Disease Diversity Coalition on an initiative to identify and overcome challenges faced by minority patients.
An epidemiologist from the healthcare data specialist offers perspective on how real-world data can help get to the heart of long-lasting COVID research.
This month’s list of partnerships, manufacturing facilities, new technologies and other items includes AstraZeneca, Charles River, Veeva, and other firms.
The University of California at Irvine and the data firm will work on solutions that help integrate health data for both clinical trials and patient care.
To fully reap the benefits of tech advances, a company leader advises, a life-sciences firm must embrace change and connection throughout the operation.
RSG Arrive is intended to increase clinical trial participation by offering ground transport, plane rides, hotels, visa procurement, and other services.
According to the firm, infectious-disease research advancements could be applied to discovering treatments for millions of hepatitis patients globally.
The company has deployed with several healthcare firms, emerged from stealth, named a chief commercial officer, and landed investors backing the technology.
The conference (with online and in-person content) is slated to gather professionals for deep conversations and lively collaboration on important topics.
A leader from the pharmaceutical firm talks about some of the most impactful technologies and shares a number of notable advancements made by the company.
A leader from the division of Eli Lilly explains the importance of driving greater trial inclusivity, and why collaboration is vital in making progress.
